Exhibit 5.1
| | | | |
| | 505 Montgomery Street, Suite 2000 |
| | San Francisco, California 94111-6538 |
| | Tel: +1.415.391.0600 Fax: +1.415.395.8095 |
| | www.lw.com |
| |
| | FIRM / AFFILIATE OFFICES |
| | Austin | | Milan |
| | Beijing | | Munich |
| | Boston | | New York |
| | Brussels | | Orange County |
March 21, 2024 | | Century City | | Paris |
| | Chicago | | Riyadh |
| | Dubai | | San Diego |
| | Düsseldorf | | San Francisco |
| | Frankfurt | | Seoul |
| | Hamburg | | Silicon Valley |
| | Hong Kong | | Singapore |
| | Houston | | Tel Aviv |
| | London | | Tokyo |
| | Los Angeles | | Washington, D.C. |
| | Madrid | | |
CARGO Therapeutics, Inc.
1900 Alameda De Las Pulgas, Suite 350
San Mateo, California 94403
| Re: | Registration Statement on Form S-8; 2,472,332 shares of Common Stock of CARGO Therapeutics, Inc., par value $0.001 per share |
To the addressee set forth above:
We have acted as special counsel to CARGO Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 2,472,332 shares of common stock of the Company, par value $0.001 per share (the “Shares”), issuable under the Company’s 2023 Incentive Award Plan (the “2023 Plan”) and 2023 Employee Stock Purchase Plan (together with the 2023 Plan, the “Plans”).
The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 21, 2024 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.